Chimeric Protein Targeting Checkpoint Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer, such as checkpoint inhibition therapy, often fail to effectively target cancer cells and are associated with significant side effects, limiting their therapeutic window and increasing susceptibility to other diseases.
Innovation Solution
Development of chimeric proteins with a targeting moiety that specifically binds to checkpoint proteins like PD-1, PD-L1, or PD-L2, combined with modified signaling agents like interferon-α2 or TNF-α, which are connected by linkers to enhance therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapies (checkpoint inhibition) are used to target cancer cells, then immune response is enhanced, but side effects increase and therapeutic window narrows
Solution Approach 1:
The patent applies local quality by engineering chimeric proteins with distinct functional domains: a targeting moiety that specifically binds to cancer cell surface markers (such as PD-L1, PD-L2, or B7-H3) and a signaling agent domain that delivers immune-modulating activity. This spatial separation ensures that immune stimulation occurs locally at the tumor site rather than systemically, thereby enhancing therapeutic efficacy while reducing widespread side effects.
Solution Approach 2:
The chimeric protein acts as an intermediary molecule that bridges the gap between passive checkpoint inhibitors and active immunomodulators. The targeting moiety serves as a localized anchor that recruits and activates signaling agents (such as modified cytokines or immune-stimulating domains) directly at the tumor microenvironment, mediating immune response enhancement without requiring systemic administration of potent immunomodulators that cause severe side effects.
2Reliability
If checkpoint inhibition therapy is administered, then immune response is boosted, but treatment fails in majority of patients
Solution Approach 1:
The patent employs parameter changes by modifying the signaling agent component of the chimeric protein through mutagenesis to alter its activity, stability, or binding characteristics. For example, cytokine domains may be engineered with enhanced half-life, improved receptor affinity, or reduced immunogenicity. These parameter optimizations allow the therapy to overcome resistance mechanisms in previously non-responsive patients and tailor the immune stimulation profile to different tumor types and patient populations.
Solution Approach 2:
The chimeric protein structure is segmented into modular functional domains that can be independently optimized and combined. The targeting moiety can be swapped to recognize different cancer-specific antigens (PD-L1, PD-L2, B7-H3, etc.), while the signaling agent domain can be changed to deliver different immune-modulating signals (cytokines, costimulatory molecules). This modularity enables adaptation to various cancer types and patient responses, overcoming the limitations of fixed checkpoint inhibitors.
3Object-affected harmful factors
If targeted therapy is used to improve cancer cell specificity, then side effects are reduced, but therapeutic window is narrowed
Solution Approach 1:
The chimeric protein design enables continuous useful action by incorporating signaling agents with extended half-lives and sustained activity at the tumor site. The targeted moiety ensures continuous localization to cancer cells, while the signaling domain maintains prolonged immune stimulation through mechanisms such as slow-release cytokine activity or sustained receptor engagement. This continuous localized action extends the effective therapeutic window without requiring frequent dosing or systemic circulation of therapeutic agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric proteins provide targeted therapy with reduced side effects, improving treatment outcomes for cancer and other diseases by specifically targeting immune checkpoint proteins, thereby enhancing the immune response against cancer cells.
Implementation Method 1
a recognition domain (e.g. antigen recognition domains, including without limitation, various antibody formats, inclusive of single-domain antibodies) which specifically bind to a target (e.g. antigen, receptor) of interest
Data Source
AI summary
The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.